PT  - JOURNAL ARTICLE
AU  - F Gachon
AU  - C Nicolas
AU  - J C Maurizis
AU  - M Verny
AU  - J L Chabard
AU  - M Faurie
AU  - G Gaillard
TI  - Disposition and metabolism of letosteine in rats.
DP  - 1988 Nov 01
TA  - Drug Metabolism and Disposition
PG  - 853--857
VI  - 16
IP  - 6
4099  - http://dmd.aspetjournals.org/content/16/6/853.short
4100  - http://dmd.aspetjournals.org/content/16/6/853.full
SO  - Drug Metab Dispos1988 Nov 01; 16
AB  - The metabolism and disposition of letosteine, labeled either with 14C or 35S, has been investigated in Sprague-Dawley rats. In separate experiments, rats received 20 mg/kg, iv or orally, [14C]letosteine or [35S]letosteine. Radioactivity was rapidly excreted, mainly in urine, after iv and oral administration. Recovery of radioactivity from 0-72-hr excreta averaged 95% after both routes of [14C]letosteine administration, whereas only 50% was recovered when [35S]letosteine was administered. 14CO2 accounted for about 7.3% (iv) and 5.1% (po) of the dose of [14C]letosteine. Comparison of the iv and oral areas under the plasma 14C radioactivity concentration-time curves suggested that oral absorption of letosteine was complete. Analysis of the radioactivity content of urine showed that letosteine undergoes rapid and extensive metabolism. Several metabolites were identified by TLC, HPLC, and MS. The findings are consistent with a splitting of the ester group of letosteine and subsequent cleavage of the thiazolidinyl ring, yielding cysteine, hypotaurine, taurine, and inorganic sulfate. The metabolite derived from the side chain was identified in the urine as 3-(hydroxycarbonylmethylthio)propanoic acid. It undergoes further oxidation into sulfoxide and sulfone derivatives, which are also present in the urine.